151
Participants
Start Date
May 3, 2019
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2026
CPI-818
Interleukin-2 inducible T-cell Kinase Inhibitor
Concord Repatriation General Hospital, Concord
Liverpool Hospital, Liverpool
Epworth Healthcare, Melbourne
Royal Adelaide Hospital, Adelaide
University of Pittsburgh, Pittsburgh
Gachon University, Incheon
Ohio State University, Columbus
Inje University Busan-Paik Hospital, Busan
University of Michigan, Ann Arbor
Pusan National University Hospital, Busan
Washington University, St Louis
Stanford University, Palo Alto
Beijing Friendship Hospital, Beijing
Beijing Boren Hospital, Beijing
Beijing Cancer Hospital, Beijing
Shanghai East Hospital, Pudong
Henan Cancer Hospital, Henan
Hackensack University Medical Center, Hackensack
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Seoul St. Mary's Hospital, Seoul
Lead Sponsor
Corvus Pharmaceuticals, Inc.
INDUSTRY